Do Trials Support Cannabis for Dementia Symptoms?

PostedMarch 12, 2026

UpdatedMarch 12, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Interest in medical cannabis as a potential treatment for dementia symptoms has grown in recent years. However, according to NHS and NICE guidance, current evidence does not support using cannabis-based medical products, including THC, CBD, or nabilone, to manage dementia or behavioural and psychological symptoms such as agitation, anxiety, or sleep problems (NICE NG97; NICE NG144).

What The Evidence Shows

According to a 2023 NICE surveillance report, recommendations remain unchanged because studies to date have not demonstrated clear or consistent benefits. Both NICE and NHS confirm that cannabis-based medicines should only be prescribed for a limited number of conditions, including severe epilepsy, chemotherapy-induced nausea, and spasticity in multiple sclerosis, not dementia (NHS Guidance).

The Alzheimer’s Society UK also concludes that research does not support cannabis or CBD oil to prevent, slow, or treat dementia. It highlights that most trials are small, early stage, and limited by safety and dosing uncertainties (Alzheimer’s Society).

A 2023 double-blind trial involving older adults with dementia found no significant improvement in behavioural symptoms or quality of life compared with placebo, although mild agitation improvements were noted (PubMed Study).

Other small studies between 2023 and 2025, including Swiss and European trials of THC/CBD oils, suggest cannabinoids may be well tolerated, but results are inconsistent and not clinically meaningful. Systematic reviews and meta-analyses confirm that findings remain inconclusive, and potential side effects such as drowsiness or confusion can be problematic for frail or elderly patients (Meta-Analysis).

What Experts Recommend

NICE and the World Health Organization emphasise that cannabinoids should only be used within research settings, not routine care. Evidence gaps remain around long-term safety, cognitive effects, and interactions with other medications. As of 2025, there are no licensed or recommended cannabis-based treatments for dementia symptoms in the UK.

The Clinical Bottom Line

NICE and NHS do not recommend cannabis-based products for dementia.

Evidence from 2023–2025 trials remain inconclusive, with small sample sizes and mixed results.

Modest improvements in agitation were observed in some studies, but no consistent benefit for mood, sleep, or quality of life.

Potential risks include confusion, drowsiness, and falls in older adults.

Current use should be limited to regulated clinical trials under specialist supervision.

Educational Context: AlleviMed

Educational platforms such as AlleviMed provide information about how medical cannabis eligibility is assessed within UK regulatory frameworks. They help patients understand that these treatments are currently restricted to specific, licensed conditions, and that dementia is not among them. AlleviMed focuses on education and eligibility guidance only, not clinical prescribing or treatment services.

Takeaway

Although early studies continue to explore whether cannabinoids could ease agitation or distress in dementia, the scientific consensus is firm. Current evidence does not justify medical cannabis for dementia symptoms. The safest, most effective care remains centred on evidence-based dementia management plans, behavioural support, and guidance from qualified healthcare professionals.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.